Ask AI
ProCE Banner Activity

EMPOWER: Treatment Satisfaction of People Living With Virologically Suppressed HIV on LA ART Who Switched to Daily Oral BIC/FTC/TAF

Conference Coverage
Slideset

In this phase IV trial of 33 people who chose to switch from virologically suppressive LA CAB plus RPV to daily oral BIC/FTC/TAF, adverse events, primarily related to the injection site, were the most common reason for deciding to switch, with participants reporting improved treatment satisfaction post switch.

Released: October 23, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare